Evaluation of the safety and effectiveness of direct-acting oral anticoagulants in patients with atrial fibrillation and coexisting valvular heart disease

ML Hampton, KB Tellor, AL Armbruster… - American Journal of …, 2020 - Springer
Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …
被引用次数：9 相关文章

Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease

ML Hampton, KB Tellor… - … devices, and other …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease.

ML Hampton, KB Tellor, AL Armbruster… - American Journal of …, 2020 - europepmc.org
Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease

ML Hampton, KB Tellor, AL Armbruster… - American Journal of …, 2020 - collections.uhsp.edu
Background: Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …